177 related articles for article (PubMed ID: 18347287)
1. Primary erythermalgia as a sodium channelopathy: screening for SCN9A mutations: exclusion of a causal role of SCN10A and SCN11A.
Drenth JP; Te Morsche RH; Mansour S; Mortimer PS
Arch Dermatol; 2008 Mar; 144(3):320-4. PubMed ID: 18347287
[TBL] [Abstract][Full Text] [Related]
2. SCN9A mutations define primary erythermalgia as a neuropathic disorder of voltage gated sodium channels.
Drenth JP; te Morsche RH; Guillet G; Taieb A; Kirby RL; Jansen JB
J Invest Dermatol; 2005 Jun; 124(6):1333-8. PubMed ID: 15955112
[TBL] [Abstract][Full Text] [Related]
3. Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia.
Yang Y; Wang Y; Li S; Xu Z; Li H; Ma L; Fan J; Bu D; Liu B; Fan Z; Wu G; Jin J; Ding B; Zhu X; Shen Y
J Med Genet; 2004 Mar; 41(3):171-4. PubMed ID: 14985375
[TBL] [Abstract][Full Text] [Related]
4. Treatment with carbamazepine and gabapentin of a patient with primary erythermalgia (erythromelalgia) identified to have a mutation in the SCN9A gene, encoding a voltage-gated sodium channel.
Natkunarajah J; Atherton D; Elmslie F; Mansour S; Mortimer P
Clin Exp Dermatol; 2009 Dec; 34(8):e640-2. PubMed ID: 19549232
[TBL] [Abstract][Full Text] [Related]
5. No mutations in the voltage-gated NaV1.7 sodium channel alpha1 subunit gene SCN9A in familial complex regional pain syndrome.
de Rooij AM; Gosso MF; Alsina-Sanchis E; Marinus J; van Hilten JJ; van den Maagdenberg AM
Eur J Neurol; 2010 Jun; 17(6):808-14. PubMed ID: 20074229
[TBL] [Abstract][Full Text] [Related]
6. Compound heterozygosity in sodium channel Nav1.7 in a family with hereditary erythermalgia.
Samuels ME; te Morsche RH; Lynch ME; Drenth JP
Mol Pain; 2008 Jun; 4():21. PubMed ID: 18518989
[TBL] [Abstract][Full Text] [Related]
7. Yield of peripheral sodium channels gene screening in pure small fibre neuropathy.
Eijkenboom I; Sopacua M; Hoeijmakers JGJ; de Greef BTA; Lindsey P; Almomani R; Marchi M; Vanoevelen J; Smeets HJM; Waxman SG; Lauria G; Merkies ISJ; Faber CG; Gerrits MM
J Neurol Neurosurg Psychiatry; 2019 Mar; 90(3):342-352. PubMed ID: 30554136
[TBL] [Abstract][Full Text] [Related]
8. A novel SCN9A mutation responsible for primary erythromelalgia and is resistant to the treatment of sodium channel blockers.
Wu MT; Huang PY; Yen CT; Chen CC; Lee MJ
PLoS One; 2013; 8(1):e55212. PubMed ID: 23383113
[TBL] [Abstract][Full Text] [Related]
9. A Novel SCN9A Mutation (F826Y) in Primary Erythromelalgia Alters the Excitability of Nav1.7.
Wu B; Zhang Y; Tang H; Yang M; Long H; Shi G; Tang J; Shi X
Curr Mol Med; 2017; 17(6):450-457. PubMed ID: 28990532
[TBL] [Abstract][Full Text] [Related]
10. Erythromelalgia caused by the missense mutation p.Arg220Pro in an alternatively spliced exon of SCN9A (NaV1.7).
Deuis JR; Kumble S; Keramidas A; Ragnarsson L; Simons C; Pais L; White SM; Vetter I
Hum Mol Genet; 2024 Jan; 33(2):103-109. PubMed ID: 37721535
[TBL] [Abstract][Full Text] [Related]
11. Congenital insensitivity to pain: novel SCN9A missense and in-frame deletion mutations.
Cox JJ; Sheynin J; Shorer Z; Reimann F; Nicholas AK; Zubovic L; Baralle M; Wraige E; Manor E; Levy J; Woods CG; Parvari R
Hum Mutat; 2010 Sep; 31(9):E1670-86. PubMed ID: 20635406
[TBL] [Abstract][Full Text] [Related]
12. [From gene to disease; primary erythermalgia--a neuropathic disease as a consequence of mutations in a sodium pump gene].
Drenth JP; te Morsche RH; Michiels JJ
Ned Tijdschr Geneeskd; 2006 Jan; 150(4):194-6. PubMed ID: 16471234
[TBL] [Abstract][Full Text] [Related]
13. Pediatric Erythromelalgia and SCN9A Mutations: Systematic Review and Single-Center Case Series.
Arthur L; Keen K; Verriotis M; Peters J; Kelly A; Howard RF; Dib-Hajj SD; Waxman SG; Walker SM
J Pediatr; 2019 Mar; 206():217-224.e9. PubMed ID: 30416015
[TBL] [Abstract][Full Text] [Related]
14. Genetic heterogeneity and exclusion of a modifying locus at 2q in a family with autosomal dominant primary erythermalgia.
Burns TM; Te Morsche RH; Jansen JB; Drenth JP
Br J Dermatol; 2005 Jul; 153(1):174-7. PubMed ID: 16029345
[TBL] [Abstract][Full Text] [Related]
15. Mutations in sodium-channel gene SCN9A cause a spectrum of human genetic pain disorders.
Drenth JP; Waxman SG
J Clin Invest; 2007 Dec; 117(12):3603-9. PubMed ID: 18060017
[TBL] [Abstract][Full Text] [Related]
16. Infrequent SCN9A mutations in congenital insensitivity to pain and erythromelalgia.
Klein CJ; Wu Y; Kilfoyle DH; Sandroni P; Davis MD; Gavrilova RH; Low PA; Dyck PJ
J Neurol Neurosurg Psychiatry; 2013 Apr; 84(4):386-91. PubMed ID: 23129781
[TBL] [Abstract][Full Text] [Related]
17. Pain behavior in SCN9A (Nav1.7) and SCN10A (Nav1.8) mutant rodent models.
Xue Y; Chidiac C; Herault Y; Gaveriaux-Ruff C
Neurosci Lett; 2021 May; 753():135844. PubMed ID: 33775738
[TBL] [Abstract][Full Text] [Related]
18. SCN9A mutations in paroxysmal extreme pain disorder: allelic variants underlie distinct channel defects and phenotypes.
Fertleman CR; Baker MD; Parker KA; Moffatt S; Elmslie FV; Abrahamsen B; Ostman J; Klugbauer N; Wood JN; Gardiner RM; Rees M
Neuron; 2006 Dec; 52(5):767-74. PubMed ID: 17145499
[TBL] [Abstract][Full Text] [Related]
19. Autosomal dominant erythermalgia associated with a novel mutation in the voltage-gated sodium channel alpha subunit Nav1.7.
Michiels JJ; te Morsche RH; Jansen JB; Drenth JP
Arch Neurol; 2005 Oct; 62(10):1587-90. PubMed ID: 16216943
[TBL] [Abstract][Full Text] [Related]
20. Novel SCN9A mutations underlying extreme pain phenotypes: unexpected electrophysiological and clinical phenotype correlations.
Emery EC; Habib AM; Cox JJ; Nicholas AK; Gribble FM; Woods CG; Reimann F
J Neurosci; 2015 May; 35(20):7674-81. PubMed ID: 25995458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
